Abstract
Background Comorbidity between different subtypes of functional gastrointestinal disorders(FGIDs) is of high prevalence in clinical practice. Heterogeneity of clinical appearances has led to difficulty in individualized diagnosis and comprehensive management of FGIDs.
Aims To discover the hidden clinical patterns of patients with comorbidity between functional dyspepsia(FD) and irritable bowel syndrome(IBS).
Methods In a retrospective cross-section study, a self-report questionnaire that consist of items indicating 5 different assessing domains including gastrointestinal discomforts, systemic discomforts, psychological disorders, and environmental aggravated factors was used as basic instrument for clinical assessment. With item response theory, the theoretical framework of assessment was evaluated, and latent traits of patient were quantified in the simulated computerized adaptive testing. Latent class analysis was used for uncovering the hidden patterns over the heterogenous clinical appearances. And differences among the profiles were compared referring to the spectrum of clinical appearances and the clinical diagnosis.
Results With 996 patients enrolled in the study, the validity and reliability of the instrument were evaluated as adequate (Cronbach’s alpha indices =0.72, Split-half reliability =0.84). The construct validity was also evaluated to be adequate with Chi-square/df=3.45, CFI=0.92, GFI=0.96, RMSEA=0.05, TLI=0.90, RMR=0.02. The 7-profile model was evaluated to be with better fitness with Entropy=0.98, Lo-Mendell-Rubin likelihood ratio test-p value<0.01, Bootstrap likelihood ratio test-p value<0.01. And the patterns detailed the heterogeneity of clinical appearance of FGIDs patients either in general condition or discomfort in specific dimension.
Conclusions With application of multidimensional variable analysis, this article summarized the hidden patterns beneath the heterogenous clinical features. And quantitative approaches helped equip clinician with individualized and comprehensive tool in the management of complex diseases such as FGIDs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Guangdong Basic and Applied Basic Research Foundation(No.2023A1515011432);The Guangzhou Science and Technology Planning Project (No.2023A04J0627);The Natural Science Foundation of China (No.82004256, No.81774264); the China Postdoctoral Science Foundation（No. 2021M691263).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Clinical Research and Ethics Committee at the First affiliated Hospital of Guangzhou University of Chinese Medicine. (NO.AF/JD-01/05)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
The data used to support the findings of this study are available from the first author(mail:.zy1717086{at}163.com) upon request.
